Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.
Also called NCT03815292
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 276 participants
- Sponsor
- Materia Medica Holding
- Registry
-
NCT03815292
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT03815292. Randomized; quadruple masking; primary purpose treatment. Start 2018-10-19 (actual); primary completion 2020-01-27 (actual). Results posted on 2021-02-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
- Condition
- Mild Cognitive Impairment
- Condition
- Ischemic Stroke
- Intervention (Drug)
- MMH-MAP
- Intervention (Drug)
- Placebo
- Lead sponsor
- Materia Medica Holding
Record details
- Record id
cardio:ct-nct03815292- Content hash
a9f3bca3d8b4245793c213f39ef6d8a8f76f1176d2bfed2661e33e41acb83aa5